H. Lundbeck A/S: all 276 studies

Page 3 of 3. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy SubjectsCompletedNCT02231450Phase 1
• Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With SchizophreniaCompletedNCT02202226Phase 1
• Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With SchizophreniaCompletedNCT02202213Phase 1
• Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.CompletedNCT02199431Phase 1
• Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed UseCompletedNCT02197598Phase 4
• Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary CareTerminatedNCT02195817Phase 4
• Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)CompletedNCT02179931Phase 1
• Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet SyndromeWithdrawnNCT02174094Phase 3
• Real Life Assessment of Abilify MaintenaTerminatedNCT02131415
• Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy SubjectsCompletedNCT02122692Phase 1
• Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy WomenCompletedNCT02112903Phase 1
• D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer CompoundCompletedNCT02093169Phase 1
• Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male SubjectsCompletedNCT02072278Phase 1
• Absolute Bioavailability of Lu AE58054 in Healthy SubjectsCompletedNCT02019394Phase 1
• Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian SubjectsCompletedNCT01975779Phase 1
• Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol ChallengeCompletedNCT01969617Phase 1
• Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy SubjectsCompletedNCT01934166Phase 1
• Safety, Efficacy and Pharmacokinetics of ALD403CompletedNCT01772524Phase 1
• Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and WomenCompletedNCT01676571Phase 1
• Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenCompletedNCT01652313Phase 1
• Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in ControlsCompletedNCT01607125Phase 1
• Safety Tolerability and Pharmacokinetics of ALD403CompletedNCT01579383Phase 1
• A Multi-Center, Open-Label StudyWithdrawnNCT01468259Phase 1
• A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive DisorderCompletedNCT01427439
• An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile SpasmsWithdrawnNCT01413711Phase 4
• Bioequivalence Study Comparing Two Formulations of EscitalopramCompletedNCT01395433Phase 1
• Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's DiseaseWithdrawnNCT01331122Phase 1/2
• Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic DoseCompletedNCT01327066Phase 1
• Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With FibromyalgiaCompletedNCT01323374Phase 2
• Safety and Efficacy of Zicronapine in Patients With SchizophreniaCompletedNCT01295372Phase 3
• Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of DroxidopaCompletedNCT01149629Phase 1
• Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive DisorderCompletedNCT01148472Phase 4
• A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)CompletedNCT01116141Phase 2
• Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic StrokeCompletedNCT01104467Phase 2
• A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With EpilepsyCompletedNCT01079351Phase 1
• Sabril Patient RegistryCompletedNCT01073579
• Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOnCompletedNCT01055379Phase 4
• Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's DiseaseCompletedNCT01019421Phase 2
• Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's AtaxiaCompletedNCT01016366Phase 2
• Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic StrokeCompletedNCT00870844Phase 1
• Sertindole in Asian Patients With SchizophreniaCompletedNCT00864045Phase 3
• Bifeprunox Extension to Extension Study in Patients With SchizophreniaTerminatedNCT00861497Phase 3
• Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesCompletedNCT00855686Phase 4
• Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With SchizophreniaCompletedNCT00810667Phase 2
• Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic StrokeCompletedNCT00790920Phase 3
• Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety DisorderCompletedNCT00788034Phase 3
• Efficacy and Safety of Lu AA39959 in Patients With Bipolar DepressionTerminatedNCT00771134Phase 2
• Efficacy of Lu 31-130 in Patients With SchizophreniaCompletedNCT00770744Phase 2
• Efficacy of Lu 31-130 in Patients With SchizophreniaCompletedNCT00768326Phase 2
• Efficacy and Safety of Lu AA34893 in Patients With Major Depressive DisorderTerminatedNCT00766870Phase 2
• Safety Study of an Antipsychotic, Sertindole, to Treat SchizophreniaCompletedNCT00763438Phase 4
• Study on Metabolic Parameters of Sertindole in Patients With SchizophreniaCompletedNCT00759460Phase 3
• Exploratory Cognition Study of Sertindole in Patients With SchizophreniaCompletedNCT00759421Phase 3
• Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic StrokeCompletedNCT00756249Phase 1
• Efficacy of Bifeprunox in Patients With SchizophreniaTerminatedNCT00704509Phase 3
• Efficacy of Bifeprunox in Patients With SchizophreniaTerminatedNCT00658645Phase 3
• A Study to Assess CH1504 in Patients With Active Rheumatoid ArthritisCompletedNCT00658047Phase 2
• Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With SchizophreniaCompletedNCT00654706Phase 3
• Efficacy and Safety of Lu AA34893 in Patients With Bipolar DepressionTerminatedNCT00622245Phase 2
• Dose-finding Study With Lu AA24530 in Major Depressive DisorderCompletedNCT00599911Phase 2
• Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)TerminatedNCT00420810Phase 3
• Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)TerminatedNCT00266357Phase 2
• MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)CompletedNCT00266344Phase 2
• A Study of Gaboxadol in Primary InsomniaCompletedNCT00209963Phase 3
• A Prospective Open-Label Extension Study of Gaboxadol in Primary InsomniaCompletedNCT00209950Phase 3
• A Prospective Active-Reference Study of Gaboxadol in Primary InsomniaCompletedNCT00209937Phase 3
• A Study of Gaboxadol in Primary InsomniaCompletedNCT00209924Phase 3
• A Study of Gaboxadol in Primary InsomniaCompletedNCT00209846Phase 3
• An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)CompletedNCT00103818Phase 3
• Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)CompletedNCT00102167Phase 3
• An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)WithdrawnNCT00102154Phase 3
• Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)CompletedNCT00095069Phase 3
• Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)CompletedNCT00095043Phase 3
• Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)TerminatedNCT00094666Phase 3
• Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)CompletedNCT00094627Phase 3
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00093951Phase 2

← H. Lundbeck A/S overview and focus areas